Understanding the versatility of the ExoLiver® platform to study the pathobiology and new therapeutic options for liver diseases.
The study describes the benefits of using the ExoLiver® platform to simulate the human liver sinusoid on a chip.
The study describes the benefits of using the ExoLiver® platform to simulate the human liver sinusoid on a chip.
Barcelona Liver Bioservices (BLB) announced today the presentation of a poster introducing the BLB’s proprietary experimental model of nonalcoholic steatohepatitis (NASH) at the 42nd annual meeting of the Spanish Association for the Study of the Liver (AEEH), held in Madrid, Spain.
Barcelona Liver Bioservices (BLB) announced today a non-exclusive partnership with the biopharmaceutical company Gilead Sciences to characterize the effects of novel chemical entities developed by Gilead for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH).